OnKure Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
OnKure reported Q3 2026 net loss of $17.8M ($0.36/share) on R&D expenses of $15.1M, with cash position of $163.3M as of September 30, 2026 (providing runway into 2029). The company announced initiation of PANORAMA, a large-scale observational registry for vascular anomalies, and confirmed IND submission plans for two next-generation PI3K inhibitors—OKI-355 (vascular anomalies) and OKI-345 (breast cancer)—both targeted for 1H 2027.
Why this rating
On-track pipeline progress and strong cash position ($163M, ~580% of $28M market cap) offset by expected losses and pre-IND stage. PANORAMA registry is strategic but non-revenue generating. Routine quarterly update for early-stage biotech.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.